Aarti Pharmalabs Limited has informed the Exchange regarding Appointment of Ms as Non- Executive Independent Director of the company w.e.f. August 12, 2025.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Pharmalabs reported its Q1 FY26 (quarter ended June 30, 2025) results alongside several board decisions. Standalone revenue from operations fell to ₹375.31 crore from ₹393.49 crore in Q1 FY25, but net profit rose to ₹51.22 crore from ₹47.14 crore, with EPS of ₹5.65. Consolidated revenue was ₹386.19 crore and net profit was ₹49.50 crore (EPS ₹5.46). The board approved the re-appointment of Ms. Rupal Vora as a Non-Executive Independent Director for a second 3-year term effective October 17, 2025, subject to shareholder approval. It also appointed M/s Mehta and Mehta as Secretarial Auditors for 5 years from FY 2025-26 and approved extending the company's stock option scheme to employees of subsidiary companies.
Profit growth on a lower revenue base suggests better margin management, though the year-on-year revenue dip may concern investors. The director re-appointment and auditor changes are routine governance matters with no material impact expected on the stock price.